What is a reasonable framework for new non-validated treatments?
Crossref DOI link: https://doi.org/10.1007/s11017-020-09537-6
Published Online: 2021-02-14
Published Print: 2020-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Helgesson, Gert
Funding for this research was provided by:
Karolinska Institute
Text and Data Mining valid from 2020-12-01
Version of Record valid from 2021-02-14
Article History
Accepted: 8 December 2020
First Online: 14 February 2021